$281 Million is the total value of CHI Advisors LLC's 22 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 50.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RPTX | Buy | REPARE THERAPEUTICS INC | $77,863,000 | +0.3% | 2,530,494 | +1.1% | 27.70% | -8.6% |
| PLRX | Buy | PLIANT THERAPEUTICS INC | $53,279,000 | -28.8% | 2,352,291 | +2.0% | 18.95% | -35.1% |
| INZY | New | INOZYME PHARMA INC | $26,529,000 | – | 1,009,117 | +100.0% | 9.44% | – |
| FRLN | New | FREELINE THERAPEUTICS HLDGSsponsored ads | $20,673,000 | – | 1,324,364 | +100.0% | 7.35% | – |
| AMWL | New | AMERICAN WELL CORPcl a | $7,361,000 | – | 248,352 | +100.0% | 2.62% | – |
| DTIL | Buy | PRECISION BIOSCIENCES INC | $6,251,000 | -21.8% | 1,014,840 | +5.7% | 2.22% | -28.7% |
| OVID | Buy | OVID THERAPEUTICS INC | $3,548,000 | -11.5% | 618,092 | +13.6% | 1.26% | -19.4% |
| CRVS | Buy | CORVUS PHARMACEUTICALS INC | $2,339,000 | +136.3% | 583,232 | +60.2% | 0.83% | +115.5% |
| GTHX | Buy | G1 THERAPEUTICS INC | $970,000 | -9.1% | 84,000 | +90.9% | 0.34% | -17.1% |
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS IN | $882,000 | +7.4% | 16,000 | +23.1% | 0.31% | -1.9% |
| ADVM | Buy | ADVERUM BIOTECHNOLOGIES INC | $721,000 | -30.9% | 70,000 | +40.0% | 0.26% | -37.1% |
| GBT | New | GLOBAL BLOOD THERAPEUTICS INcall | $26,000 | – | 10,000 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PRECISION BIOSCIENCES INC | 17 | Q3 2023 | 13.4% |
| OVID THERAPEUTICS INC | 17 | Q3 2023 | 5.8% |
| CORVUS PHARMACEUTICALS INC | 16 | Q2 2023 | 1.8% |
| KEZAR LIFE SCIENCES INC | 15 | Q1 2023 | 5.8% |
| PLIANT THERAPEUTICS INC | 14 | Q3 2023 | 29.2% |
| REPARE THERAPEUTICS INC | 14 | Q3 2023 | 30.3% |
| ORCHARD THERAPEUTICS PLC | 14 | Q4 2022 | 52.6% |
| LARIMAR THERAPEUTICS INC | 14 | Q3 2023 | 9.1% |
| KEROS THERAPEUTICS INC | 14 | Q3 2023 | 8.6% |
| INOZYME PHARMA INC | 13 | Q3 2023 | 9.4% |
View CHI Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Corvus Pharmaceuticals, Inc. | February 13, 2023 | 2,384,402 | 5.1% |
| Cullinan Oncology, Inc. | February 13, 2023 | 3,317,544 | 7.2% |
| Freeline Therapeutics Holdings plc | February 13, 2023 | 4,814,419 | 7.4% |
| Inozyme Pharma, Inc. | February 13, 2023 | 2,204,876 | 5.5% |
| Larimar Therapeutics, Inc. | February 13, 2023 | 3,473,366 | 8.0% |
| Oncorus, Inc. | February 13, 2023 | 2,367,436 | 9.1% |
| Orchard Therapeutics plc | February 13, 2023 | 7,987,396 | 6.3% |
| PLIANT THERAPEUTICS, INC. | February 13, 2023 | 3,199,892 | 6.6% |
| Repare Therapeutics Inc. | February 13, 2023 | 2,800,126 | 6.7% |
| VectivBio Holding AG | February 13, 2023 | 5,492,893 | 8.8% |
View CHI Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-13 |
| 13F-HR/A | 2023-08-22 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-11 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
View CHI Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.